Loading…
Access to direct-acting antivirals for the treatment of hepatitis C in a country with limited resources
To estimate the proportion of patients who access to direct-acting antivirals agents (DAAs) for the treatment of hepatitisC in Argentina and to evaluate factors associated with failure to access to treatment. We performed a cross-sectional study of DAAs prescriptions written by centers participating...
Saved in:
Published in: | Revista de Gastroenterología de México (English Edition) 2018-04, Vol.83 (2), p.208-211 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | eng ; spa |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 211 |
container_issue | 2 |
container_start_page | 208 |
container_title | Revista de Gastroenterología de México (English Edition) |
container_volume | 83 |
creator | Marciano, S Haddad, L Borzi, S M D'Amico, C Gaite, L A Aubone, M V Sirotinsky, M E Ratusnu, N Frola, M S Aparicio, M C Ríos, B Anselmo, M N Hansen, R De Filippi, S Dans, C García de Labra, L Peche, M A Strella, T M Ibáñez Duran, M García Rosales, M B Dirchwolf, M Galdame, O A Gadano, A C |
description | To estimate the proportion of patients who access to direct-acting antivirals agents (DAAs) for the treatment of hepatitisC in Argentina and to evaluate factors associated with failure to access to treatment.
We performed a cross-sectional study of DAAs prescriptions written by centers participating in the telemedicine project ECHO
-Hospital Italiano of Buenos Aires between January 2016 and February 2017.
A total of 143 consecutive prescriptions were evaluated; the global access was 70% (95% CI: 62%-77%). The only factor independently associated with failure to access to treatment was belonging to the public healthcare system [OR 4.98 (95% CI: 2.05- 12.09)] in comparison to belonging to private insurance or HMOs.
Patients with hepatitisC who belong to the public healthcare system are 4 times more likely to fail to access to treatment of hepatitisC than patients with private insurance or other kind of insurance. |
doi_str_mv | 10.1016/j.rgmx.2018.02.009 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2025798516</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2025798516</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-7406cd5d3f9bd352d733f62bd88f310d95a3c18f4afd791fec3950f8e27b102a3</originalsourceid><addsrcrecordid>eNo1kMtKAzEYRoMotlZfwIVk6WbGP8kkkyxL8QYFNwruhkwubcpcapJR-_YW1NW3OZwDH0LXBEoCRNztyrjpv0sKRJZASwB1guaUcl5wVr2fojmwmhegQMzQRUo7ABAS6DmaUSW4kBWfo83SGJcSziO2ITqTC21yGDZYDzl8hqi7hP0Ycd46nKPTuXdDxqPHW7fXOeSQ8AqHAWtsxmnI8YC_Qt7iLvQhO4ujS-MUj4VLdOaPLnf1twv09nD_unoq1i-Pz6vluthTQnJRVyCM5ZZ51VrGqa0Z84K2VkrPCFjFNTNE-kp7WyvinWGKg5eO1i0BqtkC3f5693H8mFzKTR-ScV2nBzdOqaFAea0kJ-KI3vyhU9s72-xj6HU8NP_nsB9f_GkK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2025798516</pqid></control><display><type>article</type><title>Access to direct-acting antivirals for the treatment of hepatitis C in a country with limited resources</title><source>ScienceDirect®</source><creator>Marciano, S ; Haddad, L ; Borzi, S M ; D'Amico, C ; Gaite, L A ; Aubone, M V ; Sirotinsky, M E ; Ratusnu, N ; Frola, M S ; Aparicio, M C ; Ríos, B ; Anselmo, M N ; Hansen, R ; De Filippi, S ; Dans, C García ; de Labra, L ; Peche, M A ; Strella, T M ; Ibáñez Duran, M ; García Rosales, M B ; Dirchwolf, M ; Galdame, O A ; Gadano, A C</creator><creatorcontrib>Marciano, S ; Haddad, L ; Borzi, S M ; D'Amico, C ; Gaite, L A ; Aubone, M V ; Sirotinsky, M E ; Ratusnu, N ; Frola, M S ; Aparicio, M C ; Ríos, B ; Anselmo, M N ; Hansen, R ; De Filippi, S ; Dans, C García ; de Labra, L ; Peche, M A ; Strella, T M ; Ibáñez Duran, M ; García Rosales, M B ; Dirchwolf, M ; Galdame, O A ; Gadano, A C</creatorcontrib><description>To estimate the proportion of patients who access to direct-acting antivirals agents (DAAs) for the treatment of hepatitisC in Argentina and to evaluate factors associated with failure to access to treatment.
We performed a cross-sectional study of DAAs prescriptions written by centers participating in the telemedicine project ECHO
-Hospital Italiano of Buenos Aires between January 2016 and February 2017.
A total of 143 consecutive prescriptions were evaluated; the global access was 70% (95% CI: 62%-77%). The only factor independently associated with failure to access to treatment was belonging to the public healthcare system [OR 4.98 (95% CI: 2.05- 12.09)] in comparison to belonging to private insurance or HMOs.
Patients with hepatitisC who belong to the public healthcare system are 4 times more likely to fail to access to treatment of hepatitisC than patients with private insurance or other kind of insurance.</description><identifier>ISSN: 0375-0906</identifier><identifier>EISSN: 2255-534X</identifier><identifier>DOI: 10.1016/j.rgmx.2018.02.009</identifier><identifier>PMID: 29656845</identifier><language>eng ; spa</language><publisher>Mexico</publisher><ispartof>Revista de Gastroenterología de México (English Edition), 2018-04, Vol.83 (2), p.208-211</ispartof><rights>Copyright © 2018 Asociación Mexicana de Gastroenterología. Publicado por Masson Doyma México S.A. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29656845$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Marciano, S</creatorcontrib><creatorcontrib>Haddad, L</creatorcontrib><creatorcontrib>Borzi, S M</creatorcontrib><creatorcontrib>D'Amico, C</creatorcontrib><creatorcontrib>Gaite, L A</creatorcontrib><creatorcontrib>Aubone, M V</creatorcontrib><creatorcontrib>Sirotinsky, M E</creatorcontrib><creatorcontrib>Ratusnu, N</creatorcontrib><creatorcontrib>Frola, M S</creatorcontrib><creatorcontrib>Aparicio, M C</creatorcontrib><creatorcontrib>Ríos, B</creatorcontrib><creatorcontrib>Anselmo, M N</creatorcontrib><creatorcontrib>Hansen, R</creatorcontrib><creatorcontrib>De Filippi, S</creatorcontrib><creatorcontrib>Dans, C García</creatorcontrib><creatorcontrib>de Labra, L</creatorcontrib><creatorcontrib>Peche, M A</creatorcontrib><creatorcontrib>Strella, T M</creatorcontrib><creatorcontrib>Ibáñez Duran, M</creatorcontrib><creatorcontrib>García Rosales, M B</creatorcontrib><creatorcontrib>Dirchwolf, M</creatorcontrib><creatorcontrib>Galdame, O A</creatorcontrib><creatorcontrib>Gadano, A C</creatorcontrib><title>Access to direct-acting antivirals for the treatment of hepatitis C in a country with limited resources</title><title>Revista de Gastroenterología de México (English Edition)</title><addtitle>Rev Gastroenterol Mex</addtitle><description>To estimate the proportion of patients who access to direct-acting antivirals agents (DAAs) for the treatment of hepatitisC in Argentina and to evaluate factors associated with failure to access to treatment.
We performed a cross-sectional study of DAAs prescriptions written by centers participating in the telemedicine project ECHO
-Hospital Italiano of Buenos Aires between January 2016 and February 2017.
A total of 143 consecutive prescriptions were evaluated; the global access was 70% (95% CI: 62%-77%). The only factor independently associated with failure to access to treatment was belonging to the public healthcare system [OR 4.98 (95% CI: 2.05- 12.09)] in comparison to belonging to private insurance or HMOs.
Patients with hepatitisC who belong to the public healthcare system are 4 times more likely to fail to access to treatment of hepatitisC than patients with private insurance or other kind of insurance.</description><issn>0375-0906</issn><issn>2255-534X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNo1kMtKAzEYRoMotlZfwIVk6WbGP8kkkyxL8QYFNwruhkwubcpcapJR-_YW1NW3OZwDH0LXBEoCRNztyrjpv0sKRJZASwB1guaUcl5wVr2fojmwmhegQMzQRUo7ABAS6DmaUSW4kBWfo83SGJcSziO2ITqTC21yGDZYDzl8hqi7hP0Ycd46nKPTuXdDxqPHW7fXOeSQ8AqHAWtsxmnI8YC_Qt7iLvQhO4ujS-MUj4VLdOaPLnf1twv09nD_unoq1i-Pz6vluthTQnJRVyCM5ZZ51VrGqa0Z84K2VkrPCFjFNTNE-kp7WyvinWGKg5eO1i0BqtkC3f5693H8mFzKTR-ScV2nBzdOqaFAea0kJ-KI3vyhU9s72-xj6HU8NP_nsB9f_GkK</recordid><startdate>20180401</startdate><enddate>20180401</enddate><creator>Marciano, S</creator><creator>Haddad, L</creator><creator>Borzi, S M</creator><creator>D'Amico, C</creator><creator>Gaite, L A</creator><creator>Aubone, M V</creator><creator>Sirotinsky, M E</creator><creator>Ratusnu, N</creator><creator>Frola, M S</creator><creator>Aparicio, M C</creator><creator>Ríos, B</creator><creator>Anselmo, M N</creator><creator>Hansen, R</creator><creator>De Filippi, S</creator><creator>Dans, C García</creator><creator>de Labra, L</creator><creator>Peche, M A</creator><creator>Strella, T M</creator><creator>Ibáñez Duran, M</creator><creator>García Rosales, M B</creator><creator>Dirchwolf, M</creator><creator>Galdame, O A</creator><creator>Gadano, A C</creator><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20180401</creationdate><title>Access to direct-acting antivirals for the treatment of hepatitis C in a country with limited resources</title><author>Marciano, S ; Haddad, L ; Borzi, S M ; D'Amico, C ; Gaite, L A ; Aubone, M V ; Sirotinsky, M E ; Ratusnu, N ; Frola, M S ; Aparicio, M C ; Ríos, B ; Anselmo, M N ; Hansen, R ; De Filippi, S ; Dans, C García ; de Labra, L ; Peche, M A ; Strella, T M ; Ibáñez Duran, M ; García Rosales, M B ; Dirchwolf, M ; Galdame, O A ; Gadano, A C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-7406cd5d3f9bd352d733f62bd88f310d95a3c18f4afd791fec3950f8e27b102a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; spa</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marciano, S</creatorcontrib><creatorcontrib>Haddad, L</creatorcontrib><creatorcontrib>Borzi, S M</creatorcontrib><creatorcontrib>D'Amico, C</creatorcontrib><creatorcontrib>Gaite, L A</creatorcontrib><creatorcontrib>Aubone, M V</creatorcontrib><creatorcontrib>Sirotinsky, M E</creatorcontrib><creatorcontrib>Ratusnu, N</creatorcontrib><creatorcontrib>Frola, M S</creatorcontrib><creatorcontrib>Aparicio, M C</creatorcontrib><creatorcontrib>Ríos, B</creatorcontrib><creatorcontrib>Anselmo, M N</creatorcontrib><creatorcontrib>Hansen, R</creatorcontrib><creatorcontrib>De Filippi, S</creatorcontrib><creatorcontrib>Dans, C García</creatorcontrib><creatorcontrib>de Labra, L</creatorcontrib><creatorcontrib>Peche, M A</creatorcontrib><creatorcontrib>Strella, T M</creatorcontrib><creatorcontrib>Ibáñez Duran, M</creatorcontrib><creatorcontrib>García Rosales, M B</creatorcontrib><creatorcontrib>Dirchwolf, M</creatorcontrib><creatorcontrib>Galdame, O A</creatorcontrib><creatorcontrib>Gadano, A C</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Revista de Gastroenterología de México (English Edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marciano, S</au><au>Haddad, L</au><au>Borzi, S M</au><au>D'Amico, C</au><au>Gaite, L A</au><au>Aubone, M V</au><au>Sirotinsky, M E</au><au>Ratusnu, N</au><au>Frola, M S</au><au>Aparicio, M C</au><au>Ríos, B</au><au>Anselmo, M N</au><au>Hansen, R</au><au>De Filippi, S</au><au>Dans, C García</au><au>de Labra, L</au><au>Peche, M A</au><au>Strella, T M</au><au>Ibáñez Duran, M</au><au>García Rosales, M B</au><au>Dirchwolf, M</au><au>Galdame, O A</au><au>Gadano, A C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Access to direct-acting antivirals for the treatment of hepatitis C in a country with limited resources</atitle><jtitle>Revista de Gastroenterología de México (English Edition)</jtitle><addtitle>Rev Gastroenterol Mex</addtitle><date>2018-04-01</date><risdate>2018</risdate><volume>83</volume><issue>2</issue><spage>208</spage><epage>211</epage><pages>208-211</pages><issn>0375-0906</issn><eissn>2255-534X</eissn><abstract>To estimate the proportion of patients who access to direct-acting antivirals agents (DAAs) for the treatment of hepatitisC in Argentina and to evaluate factors associated with failure to access to treatment.
We performed a cross-sectional study of DAAs prescriptions written by centers participating in the telemedicine project ECHO
-Hospital Italiano of Buenos Aires between January 2016 and February 2017.
A total of 143 consecutive prescriptions were evaluated; the global access was 70% (95% CI: 62%-77%). The only factor independently associated with failure to access to treatment was belonging to the public healthcare system [OR 4.98 (95% CI: 2.05- 12.09)] in comparison to belonging to private insurance or HMOs.
Patients with hepatitisC who belong to the public healthcare system are 4 times more likely to fail to access to treatment of hepatitisC than patients with private insurance or other kind of insurance.</abstract><cop>Mexico</cop><pmid>29656845</pmid><doi>10.1016/j.rgmx.2018.02.009</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0375-0906 |
ispartof | Revista de Gastroenterología de México (English Edition), 2018-04, Vol.83 (2), p.208-211 |
issn | 0375-0906 2255-534X |
language | eng ; spa |
recordid | cdi_proquest_miscellaneous_2025798516 |
source | ScienceDirect® |
title | Access to direct-acting antivirals for the treatment of hepatitis C in a country with limited resources |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T06%3A15%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Access%20to%20direct-acting%20antivirals%20for%20the%20treatment%20of%20hepatitis%20C%20in%20a%20country%20with%20limited%20resources&rft.jtitle=Revista%20de%20Gastroenterolog%C3%ADa%20de%20M%C3%A9xico%20(English%20Edition)&rft.au=Marciano,%20S&rft.date=2018-04-01&rft.volume=83&rft.issue=2&rft.spage=208&rft.epage=211&rft.pages=208-211&rft.issn=0375-0906&rft.eissn=2255-534X&rft_id=info:doi/10.1016/j.rgmx.2018.02.009&rft_dat=%3Cproquest_pubme%3E2025798516%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p211t-7406cd5d3f9bd352d733f62bd88f310d95a3c18f4afd791fec3950f8e27b102a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2025798516&rft_id=info:pmid/29656845&rfr_iscdi=true |